Regimmune Corporation Company
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for rare diseases and cancer by leveraging underexploited biological opportunities.
Investors
Industry:
Stem Cell Exhaustion
Technology:
Geroscience
Estimated Revenue:
Less than $1M
Investors Number:
28
Headquarters:
Japan
Employee Number:
11-50
Investor Type:
For Profit
Total Funding:
$55M
Founded Date:
2006-03-01
Last Funding Type:
Post-IPO Equity
Last Funding Date:
2017-05-10